trans-N-[4-(N-methoxy-N-methylcarbamoyl)cyclohexyl]-N-methylcarbamic acid tert-butyl ester | 400898-93-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: trans-N-[4-(N-methoxy-N-methylcarbamoyl)cyclohexyl]-N-methylcarbamic acid tert-butyl ester
• 英文别名: tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}methylcarbamate；trans-tert-butyl (4-(methoxy(methyl)carbamoyl)cyclohexyl)(methyl)carbamate
• CAS: 400898-93-3
• 化学式: C₁₅H₂₈N₂O₄
• 分子量: 300.398
• InChiKey: DDCCFLIABDSPLO-HAQNSBGRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.43
• 重原子数：
  21.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  59.08
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  trans-N-[4-(N-methoxy-N-methylcarbamoyl)cyclohexyl]-N-methylcarbamic acid tert-butyl ester 在 lithium aluminium tetrahydride 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.33h， 生成 trans-[4-(2,2-dibromovinyl)cyclohexyl]-N-methylcarbamic acid tert-butyl ester
  参考文献：
  名称：

  Cytotoxic Effects of Combination of Oxidosqualene Cyclase Inhibitors with Atorvastatin in Human Cancer Cells

  摘要：

  Ten oxidosqualene c-yclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical structure classes were evaluated as potential anticancer agents against human cancer cells from various tissue origins and nontumoral human-brain-derived endothelial cells. Inhibition of cancer cell growth was demonstrated at micromolar concentrations, comparable to the concentrations of statins necessary for antitumor effect. Human glioblastoma cells were among the most sensitive cells. These compounds were also able to decrease the proliferation of angiogenic brain-derived endothelial cells, as a model of tumor-induced neovasculation. Additive effects in human glioblastoma cells were also demonstrated for oxidosqualene cyclase inhibitors in combination with atorvastatin while maintaining selectivity against endothelial cells. Thus, not only statins targeting the 3-hydroxy-3-methylglutaryl coenzyme A reductase but also inhibitors of oxidosqualene cyclase decrease tumor growth, suggesting new therapeutic opportunities of combined anti-cholesterol agents for dual treatment of glioblastoma.

  DOI：

  10.1021/jm300256z
• 作为产物：
  描述：

  Cis-4-(Boc-Amino)Cyclohexanecarboxylic Acid 在 N-甲基吗啉 、 sodium hydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 32.5h， 生成 trans-N-[4-(N-methoxy-N-methylcarbamoyl)cyclohexyl]-N-methylcarbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] OXIME COMPOUNDS USEFUL AS T CELL ACTIVATORS
  [FR] COMPOSÉS OXIME UTILES COMME ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  本文披露了具有Formula (I)结构的肟化合物：或其药用可接受的盐、溶剂化合物、水合物、异构体、互变异构体、拉氏体、或同位素，其中R1、R2、R3、a、L、X和Y如本文所定义。还提供了包括它们的药物组合物、制备它们的方法以及用途，用于治疗或预防疾病、紊乱和状况。这些化合物是二酰甘油激酶α(DGKα)和二酰甘油激酶ζ(DGKζ)的抑制剂，并且在治疗与DGKα和/或DGKζ活性相关的疾病、紊乱和状况方面是有用的。特别地，这些化合物对于治疗病毒感染和增生性疾病，如癌症，是有用的。

  公开号：

  WO2021258010A1

文献信息

• 2,3-oxidosqualene-lanosterol cyclase inhibitors
  申请人：——

  公开号：US20020045777A1

  公开（公告）日：2002-04-18

  The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及氨基环己醇衍生物，用于治疗和/或预防与2,3-氧化甾二烯-鲨烯合酶相关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌病、胆结石、肿瘤和/或增生性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• Substituted cyclohexane derivatives
  申请人：——

  公开号：US20030186984A1

  公开（公告）日：2003-10-02

  The present invention relates to compounds of formula (I) 1 wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , U, V, m, n and o are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the 2,3-oxidosqualene-lanosterol cyclase biosynthetic pathway such as hypercholesterolemia and hyperlipemia.

  本发明涉及式(I)的化合物，其中A1、A2、A3、A4、A5、A6、U、V、m、n和o如规范中定义的那样，以及其药学上可接受的盐。这些化合物对于治疗和/或预防与2,3-氧化甾二烯-鲨烯合成途径相关的疾病，如高胆固醇血症和高脂血症，是有用的。
• 2,3-Oxidosqualene-lanosterol cyclase inhibitors
  申请人：Ackermann Jean

  公开号：US20050176766A1

  公开（公告）日：2005-08-11

  The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及氨基环己醇衍生物，用于治疗和/或预防与2,3-氧化角鲨烯-鲨烯环化酶相关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌感染、胆结石、肿瘤和/或过度增殖性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• NOVEL AMINOCYCLOHEXANE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1311475A1

  公开（公告）日：2003-05-21
• AMINOCYCLOHEXANE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1311475B1

  公开（公告）日：2008-08-06